Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen: „Eine Lanze für die Parazentese brechen“

Michael Janusz Koss; Matthias Bolz; Albert J. Augustin; Frank Koch; Peter Szurman; Boris Stanzel; Sascha Fauser; Stefan Mennel; Urs Vossmerbäumer; Marc D. de Smet; Fabian Höhn; Michael Küchle; Birgit Lorenz; Mathias Lüke; Lyubomyr Lytvynchuk; Carsten H. Meyer; Christoph Paul; Eduardo B. Rodrigues; Norbert Schrage; Claus Zehetner

doi:10.1055/a-0972-9747

Klinische Monatsblätter für Augenheilkunde, Inhaltsverzeichnis

Klin Monbl Augenheilkd 2020; 237(01): 90-94
DOI: 10.1055/a-0972-9747

Offene Korrespondenz

Georg Thieme Verlag KG Stuttgart · New York

Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen: „Eine Lanze für die Parazentese brechen“

Safety, Efficacy and Protective Aspects of an Add-on Paracentesis during Intravitreal Injections

Autor*innen

Michael Janusz Koss

¹Augenheilkunde, Augenzentrum Nymphenburger Höfe
Matthias Bolz

²Augenklinik, Johannes-Kepler-Universität, Linz, Österreich
Albert J. Augustin

³Augenklinik, Städtisches Klinikum Karlsruhe
Frank Koch

⁴Augenklinik, Klinikum der Johann Wolfgang Goethe Universität, Frankfurt am Main
Peter Szurman

⁵Augenklinik Sulzbach, Knappschaftsklinikum Saar GmbH, Sulzbach/Saar
Boris Stanzel

⁵Augenklinik Sulzbach, Knappschaftsklinikum Saar GmbH, Sulzbach/Saar
Sascha Fauser

⁶Zentrum für Augenheilkunde, Universität zu Köln
Stefan Mennel

⁷Augenklinik, Klinikum Feldkirch, Österreich
Urs Vossmerbäumer

⁸Augenklinik, Universitätsmedizin Mainz
Marc D. de Smet

⁹Retina and Inflammation Unit, Clinique de Montchoisi, Lausanne, Schweiz
Fabian Höhn

¹⁰Augenklinik, Marienhospital Osnabrück
Michael Küchle

¹¹Augenpraxisklinik Erlangen, Erlangen
Birgit Lorenz

¹²Augenklinik, Justus-Liebig-Universität, Gießen
Mathias Lüke

¹³Augenheilkunde am Rheincenter, Köln
Lyubomyr Lytvynchuk

¹²Augenklinik, Justus-Liebig-Universität, Gießen
Carsten H. Meyer

¹⁴Smartlook Augenärzte, Aarau, Schweiz
Christoph Paul

¹⁵Augenklinik, Philipps-Universität, Marburg
Eduardo B. Rodrigues

¹⁶Augenklinik, Saint Louis Universität, Saint Louis, MO, USA
Norbert Schrage

¹⁷Augenklinik Köln-Merheim, Köln
Claus Zehetner

¹⁸Universitätsklinik für Augenheilkunde und Optometrie, Innsbruck, Österreich

Abstract

Volltext

Referenzen

Literatur
1 Rosenfeld PJ, Brown DM, Heier JS. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
2 Hollands H, Wong J, Bruen R. et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42: 807-811
3 Gismondi M, Salati C, Salvetat ML. et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009; 18: 658-661 doi:10.1097/IJG.0b013e31819c4893
4 Meyer CH, Rodrigues EB, Aguni J. et al. Scleral incisions evaluated by with anterior segment optical coherence tomography. Am J Ophthalmol 2009; 148: 321 doi:10.1016/j.ajo.2009.04.014
5 Rodrigues EB, Grumann jr. A, Penha FM. et al. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther 2011; 27: 197-203
6 Degenring RF, Sauder G. Vitreous prolapse and IOL dislocation during intravitreal injection of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1043-1044
7 Viestenz A, Küchle M, Behrens-Baumann W. Bulbusexplosion durch intravitreale Injektion. Klin Monatsbl Augenheilkd 2008; 225: 1087-1090
8 Sharei V, Höhn F, Köhler T. et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol 2010; 20: 174-179
9 Lorenz K, Zwiener I, Mirshahi A. Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1573-1577 doi:10.1007/s00417-010-1490-y
10 Ziemssen F, Eter N, Fauser S. et al. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]. Ophthalmologe 2015; 112: 246-254 doi:10.1007/s00347-014-3217-7
11 Munk MR, Ceklic L, Ebneter A. et al. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 2016; 94: e757-e764 doi:10.1111/aos.13157
12 Horsley MB, Mandava N, Maycotte MA. et al. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2010; 150: 558-561.e1 doi:10.1016/j.ajo.2010.04.029
13 Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 2013; 44: 460-464 doi:10.3928/23258160-20130909-07
14 Beck M, Munk MR, Ebneter A. et al. Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol 2016; 167: 10-17 doi:10.1016/j.ajo.2016.04.003
15 Kopić A, Biuk D, Barać J. et al. Retinal nerve fiber layer thickness in glaucoma patients treated with multiple intravitreal anti-VEGF (bevacizumab) injections. Acta Clin Croat 2017; 56: 406-414 doi:10.20471/acc.2017.56.03.07
16 Prager SG, Lammer J, Mitsch C. et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmol 2018; 96: e195-e200 doi:10.1111/aos.13520
17 Lanzl I, Kotliar K. [Can Anti-VEGF Injections Cause Glaucoma or Ocular Hypertension?]. Klin Monatsbl Augenheilkd 2017; 234: 191-193 doi:10.1055/s-0043-101819
18 Meyer CH, Liu Z, Brinkmann C. et al. Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0-cc syringe. Acta Ophthalmol 2012; 90: e165-e166 doi:10.1111/j.1755-3768.2010.02072.x
19 Gerding H, Timmermann M. Accuracy and precision of intravitreally injected ranibizumab doses: an experimental study. Klin Monatsbl Augenheilkd 2010; 227: 269-272
20 Kotliar K, Maier M, Bauer S. et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007; 85: 777-781
21 Knip MM, Välimäki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol 2012; 90: 254-258 doi:10.1111/j.1755-3768.2010.01904.x
22 Van der Lelij A, Rothova A. Diagnostic anterior chamber paracentesis in uveitis: a safe procedure?. Br J Ophthalmol 1997; 81: 976-979
23 Carnahan MC, Platt LW. Serial paracenteses in the management of acute elevations of intraocular pressure. Ophthalmology 2002; 109: 1604-1606
24 Lam DS, Chua JK, Tham CC. et al. Efficacy and safety of immediate anterior chamber paracentesis in the treatment of acute primary angle-closure glaucoma: a pilot study. Ophthalmology 2002; 109: 64-70
25 Arnavielle S, Creuzot-Garcher C, Bron AM. Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol 2007; 245: 345-350
26 Cheung CM, Durrani OM, Murray PI. The safety of anterior chamber paracentesis in patients with uveitis. Br J Ophthalmol 2004; 88: 582-583
27 Trivedi D, Denniston AK, Murray PI. Safety profile of anterior chamber paracentesis performed at the slit lamp. Clin Exp Ophthalmol 2011; 39: 725-728 doi:10.1111/j.1442-9071.2011.02565.x
28 Kitazawa K, Sotozono C, Koizumi N. et al. Safety of anterior chamber paracentesis using a 30-gauge needle integrated with a specially designed disposable pipette. Br J Ophthalmol 2017; 101: 548-550 doi:10.1136/bjophthalmol-2016-309650
29 Azuara-Blanco A, Katz LJ. Infectious keratitis in a paracentesis tract. Ophthalmic Surg Lasers 1997; 28: 332-333
30 Helbig H, Noske W, Kleineidam M. et al. Bacterial endophthalmitis after anterior chamber paracentesis. Br J Ophthalmol 1995; 79: 866
31 Meyer CH, Rodrigues EB, Michels S. et al. Incidence of damage to the crystalline lens during intravitreal injections. J Ocul Pharmacol Ther 2010; 26: 491-495 doi:10.1089/jop.2010.0045
32 Xing L, Dorrepaal SJ, Gale J. Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Can J Ophthalmol 2014; 49: 261-266
33 Funk M, Karl D, Georgopoulos M. et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009; 116: 2393-2399 doi:10.1016/j.ophtha.2009.05.039
34 Muether PS, Hermann MM, Dröge K. et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol 2013; 156: 989-993.e2 doi:10.1016/j.ajo.2013.06.020
35 dellʼOmo R, Cassetta M, dellʼOmo E. et al. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study. Am J Ophthalmol 2012; 153: 155-161.e2
36 Rezar-Dreindl S, Eibenberger K, Pollreisz A. et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol 2017; 95: e119-e127 doi:10.1111/aos.13152
37 Garweg JG, Zandi S, Pfister IB. et al. Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma. PLoS One 2017; 12: e0182571
38 Ichiyama Y, Sawada T, Kakinoki M. et al. Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration. Ophthalmic Res 2014; 52: 234-238 doi:10.1159/000365253
39 Bach A, Filipowicz A, Gold AS. et al. Paracentesis following intravitreal drug injections in maintaining physiologic ocular perfusion pressure. Int J Ophthalmol 2017; 10: 1925-1927 doi:10.18240/ijo.2017.12.22
40 Soheilian M, Karimi S, Montahae T. et al. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. Graefes Arch Clin Exp Ophthalmol 2017; 255: 1705-1712 doi:10.1007/s00417-017-3702-1
41 Enders P, Sitnilska V, Altay L. et al. Retinal nerve fiber loss in anti-VEGF therapy for age-related macular degeneration can be decreased by anterior chamber paracentesis. Ophthalmologica 2017; 237: 111-118 doi:10.1159/000457907